التفاصيل البيبلوغرافية
| العنوان: |
Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol |
| المؤلفون: |
Andel, Daan, Lam, Marnix G.E.H., de Bruijne, Joep, Smits, Maarten L.J., Braat, Arthur J.A.T., Moelker, Adriaan, Vegt, Erik, Ruiter, Simeon J.S., Noordzij, Walter, Grazi, Gianluca, Vallati, Giulio E., Bennink, Roel J., van Delden, Otto M., Kranenburg, Onno W., Ijzermans, Jan N.M., Nijkamp, Maarten W., Erdmann, Joris I., Sciuto, Rosa, Hagendoorn, Jeroen, Borel Rinkes, Inne H.M. |
| المساهمون: |
MS HOD, Lab Translational Oncology, Researchgr. Nucleaire Geneeskunde, Cancer, MS MDL 1, MS Radiologie, Regenerative Medicine and Stem Cells, MS CGO |
| سنة النشر: |
2023 |
| مصطلحات موضوعية: |
Ho, Hepatocellular carcinoma, Holmium-166, Radiation lobectomy, Radioembolization, Unilobar radioembolization, Oncology, Genetics, Cancer Research |
| الوصف: |
Background: High dose unilobar radioembolization (also termed ‘radiation lobectomy’)—the transarterial unilobar infusion of radioactive microspheres as a means of controlling tumour growth while concomitantly inducing future liver remnant hypertrophy—has recently gained interest as induction strategy for surgical resection. Prospective studies on the safety and efficacy of the unilobar radioembolization-surgery treatment algorithm are lacking. The RALLY study aims to assess the safety and toxicity profile of holmium-166 unilobar radioembolization in patients with hepatocellular carcinoma ineligible for surgery due to insufficiency of the future liver remnant. Methods: The RALLY study is a multicenter, interventional, non-randomized, open-label, non-comparative safety study. Patients with hepatocellular carcinoma who are considered ineligible for surgery due to insufficiency of the future liver remnant (< 2.7%/min/m2 on hepatobiliary iminodiacetic acid scan will be included. A classical 3 + 3 dose escalation model will be used, enrolling three to six patients in each cohort. The primary objective is to determine the maximum tolerated treated non-tumourous liver-absorbed dose (cohorts of 50, 60, 70 and 80 Gy). Secondary objectives are to evaluate dose–response relationships, to establish the safety and feasibility of surgical resection following unilobar radioembolization, to assess quality of life, and to generate a biobank. Discussion: This will be the first clinical study to assess the unilobar radioembolization-surgery treatment algorithm and may serve as a stepping stone towards its implementation in routine clinical practice. Trial registration: Netherlands Trial Register NL8902 , registered on 2020–09-15. |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/pdf |
| اللغة: |
English |
| تدمد: |
1471-2407 |
| العلاقة: |
https://dspace.library.uu.nl/handle/1874/450089Test |
| الإتاحة: |
https://dspace.library.uu.nl/handle/1874/450089Test |
| حقوق: |
info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: |
edsbas.40ACD1BE |
| قاعدة البيانات: |
BASE |
Full Text Finder